TuHURA secures $3M bridge loan at 3% monthly interest, secured by ImmuneFx patents

TuHURA Biosciences, Inc./NV

Initial $1.5M advance from Matthew Nachtrab Revocable Trust on Oct 27, 2025; up to $3M total available.
Interest at 3% per month (36% annual); $180K loan fee plus warrants covering 10% of each advance.
Loan secured by first-priority lien on U.S. patents for ImmuneFx technology platform.
Maturity Dec 31, 2025 or 30 days after an equity raise >$12M; proceeds for working capital.
Prepayment allowed without penalty; lender may fund additional $1.5M upon written request.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

TuHURA Biosciences, Inc./NV incurred loan of up to $3,000,000 with Matthew Nachtrab Revocable Trust dated 12/18/2014 at 3% per month maturing the earlier of December 31, 2025 or on the date that is 30 days following the successful closing of an equity financing in which the Company receives gross cash.

Instrument: loan
Principal: up to $3,000,000
Counterparty: Matthew Nachtrab Revocable Trust dated 12/18/2014
Rate: 3% per month
Maturity: the earlier of December 31, 2025 or on the date that is 30 days following the successful closing of an equity financing in which the Company receives gross cash
Event: incurrence

Exact text from the filing

Pursuant to the terms of the Loan Agreement, the Lender agreed to make loans to the Company in an aggregate principal amount of up to $3,000,000 (the “Loans”) during a 30-day availability period beginning on the date of the Loan Agreement.

View on SEC.gov

306 debt financings filed in the last 30 days. Browse all debt financings →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0001193125-25-260924

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.